tetano
Editor, Senior Moderator
iScience
. 2025 Jun 13;28(7):112893.
doi: 10.1016/j.isci.2025.112893. eCollection 2025 Jul 18. Induction of hemagglutinin stalk reactive antibodies by the administration of a live-attenuated influenza virus vaccine in children
Juan Manuel Carreño[SUP] 1 2 [/SUP], Philip Meade[SUP] 1 2 [/SUP], Na Fatimata Sogodogo[SUP] 1 2 [/SUP], Kaori Sano[SUP] 1 [/SUP], Johnstone Tcheou[SUP] 1 2 [/SUP], Ariel Raskin[SUP] 1 2 [/SUP], Gagandeep Singh[SUP] 1 2 [/SUP], Miriam Fried[SUP] 1 2 [/SUP], Madhumathi Loganathan[SUP] 1 2 [/SUP], Benjamin Francis[SUP] 1 2 [/SUP], Dominika Bielak[SUP] 1 2 [/SUP], Ya Jankey Jagne[SUP] 3 [/SUP], Hadijatou J Salah[SUP] 3 [/SUP], Florian Krammer[SUP] 1 2 4 5 [/SUP], Thushan I de Silva[SUP] 3 6 7 [/SUP]
Affiliations
Early life exposures to influenza viruses may imprint a hemagglutinin group-specific signature on immunity that impacts future responses to infection or vaccination. We assessed the administration of a live attenuated influenza virus (LAIV) vaccine in children. Two LAIV formulations (2016-17 and 2017-18) containing distinct H1N1 components were used. Modest boosting of pre-existing serum stalk reactive titers and enhancement of functional antibody-dependent cellular cytotoxicity activity (ADCC) was observed. The magnitude of stalk antibody induction in children naive to influenza A viruses was low; however, LAIV induced de novo stalk antibodies, increasing the number of children seropositive to both group 1 (G1) and group 2 (G2) influenza viruses. The 2018 LAIV formulation, containing an updated H1N1 component, induced higher stalk reactive antibodies with strong ADCC effector functions to the G1 stalk. No significant changes were detected in NA-reactive antibodies in serum or in stalk- or NA-secretory IgA (sIgA) in oral fluid.
. 2025 Jun 13;28(7):112893.
doi: 10.1016/j.isci.2025.112893. eCollection 2025 Jul 18. Induction of hemagglutinin stalk reactive antibodies by the administration of a live-attenuated influenza virus vaccine in children
Juan Manuel Carreño[SUP] 1 2 [/SUP], Philip Meade[SUP] 1 2 [/SUP], Na Fatimata Sogodogo[SUP] 1 2 [/SUP], Kaori Sano[SUP] 1 [/SUP], Johnstone Tcheou[SUP] 1 2 [/SUP], Ariel Raskin[SUP] 1 2 [/SUP], Gagandeep Singh[SUP] 1 2 [/SUP], Miriam Fried[SUP] 1 2 [/SUP], Madhumathi Loganathan[SUP] 1 2 [/SUP], Benjamin Francis[SUP] 1 2 [/SUP], Dominika Bielak[SUP] 1 2 [/SUP], Ya Jankey Jagne[SUP] 3 [/SUP], Hadijatou J Salah[SUP] 3 [/SUP], Florian Krammer[SUP] 1 2 4 5 [/SUP], Thushan I de Silva[SUP] 3 6 7 [/SUP]
Affiliations
- PMID: 40620902
- PMCID: PMC12226393
- DOI: 10.1016/j.isci.2025.112893
Early life exposures to influenza viruses may imprint a hemagglutinin group-specific signature on immunity that impacts future responses to infection or vaccination. We assessed the administration of a live attenuated influenza virus (LAIV) vaccine in children. Two LAIV formulations (2016-17 and 2017-18) containing distinct H1N1 components were used. Modest boosting of pre-existing serum stalk reactive titers and enhancement of functional antibody-dependent cellular cytotoxicity activity (ADCC) was observed. The magnitude of stalk antibody induction in children naive to influenza A viruses was low; however, LAIV induced de novo stalk antibodies, increasing the number of children seropositive to both group 1 (G1) and group 2 (G2) influenza viruses. The 2018 LAIV formulation, containing an updated H1N1 component, induced higher stalk reactive antibodies with strong ADCC effector functions to the G1 stalk. No significant changes were detected in NA-reactive antibodies in serum or in stalk- or NA-secretory IgA (sIgA) in oral fluid.